Purpose: To clarify the impact of bone metabolism disorder on lumbago in Parkinson’s Disease
(PD). Methods: Data was retrospectively analyzed from 52 patients with PD in our outpatient clinic
for more than 1 year (mean age, 63 ± 4 years old; mean duration from onset, 6.3 ± 0.8 years).
Patients’ characteristics, comorbid musculoskeletal disorders, serum bone metabolism biomarkers,
and bone mineral density were examined. Results: Twenty-one PD patients (40.2%) had
chronic lumbago. Severe comptocormia and scoliosis were the most common musculosketal disorders
in this group (47.6%) affected by lumbago, followed by osteoporosis (14.3%), compression
fracture (4.8%). There was no significant difference in the duration of PD, body mass index, frequency
of falls, bone mineral density, tartrate-resistant acid phosphatase-5b, osteocalcin, and
N-terminal telopeptide between PD patients with or without chronic lumbago. Multivaritae logistic
regression analysis identified the independent predictors of chroni lumbago in PD patients as
Hoen-Yahr stage (odds ration [OR] = 2.794, 95%CI 1.103 - 7.076), and elevated serum 1,25-OH2 vitamin D level ([OR] = 0.92, 95%CI 0.86 - 98). Conclusion: Bone metabolism disorders are found
to be associated with chronic lumbago in PD patients.
References
[1]
Chaudhuri, K.R., Healy, D.G. and Schapira, A.H. (2006) Non-Motor Symptoms of Parkinson’s Disease: Diagnosis and Management. Lancet Neurology, 5, 235-245. http://dx.doi.org/10.1016/S1474-4422(06)70373-8
Broetz, D., Eichner, M., Gasser, T., Weller, M. and Steinbach, J.P. (2007) Radicular and Nonradicular Back Pain in Parkinson’s Disease: A Controlled Study. Movement Disorders, 22, 853-856. http://dx.doi.org/10.1002/mds.21439
[4]
Defazio, G., Berardelli, A., Fabbrini, Ge., Martino, D., Fincati, E., Fiaschi, A., Moretto, G., Abbruzzese, G., Marchese, R., Bonuccelli, U., Del Dotto, P., Barone, P., De Vivo, E., Albanese, A., Antonini, A., Canesi, M., Lopiano, L., Zibetti, M., Nappi, G., Martignoni, E., Lamberti, P. and Tinazzi, M. (2008) Pain as a Nonmortor Symptom of Parkinson’s Disease. Archives of Neurology, 65, 1191-1194. http://dx.doi.org/10.1001/archneurol.2008.2
[5]
Négre-Pagés, L., Regragui, W., Bouhasssira, D., Grandjean, H., Rascol, O., and for DoPaMiP Study Group (2008) Chronic Pain in Parkinson’s Disease: the Cross-Sectional French DoPaMiP Survey. Movement Disorders, 23, 1361- 1369. http://dx.doi.org/10.1002/mds.22142
[6]
Khosla, S. and Riggs, B.L. (2005) Pathophysiology of Age-Related Bone Loss and Osteoporosis. Endocrinology and Metabolism Clinics of North America, 34, 1015-1030. http://dx.doi.org/10.1016/j.ecl.2005.07.009
[7]
Genant, H.K., Wu, C.Y., van Kuijik, C. and Nevitt, M.C. (1993) Vertebral Fracture Assessment Using a Semi-Quan- titative Technique. Journal of Bone and Mineral Research, 8, 1137-1148. http://dx.doi.org/10.1002/jbmr.5650080915
[8]
Karlsen, K.H., Tandberg, E., Arsland, D. and Larsen, J.P. (2000) Health Related Quality of Life in Parkinson’s Disease: A Prospective Longitudinal Study. Journal of Neurology, Neurosurgery & Psychiatry, 69, 584-589.
http://dx.doi.org/10.1136/jnnp.69.5.584
[9]
Loge, J.H. and Kaasa, S. (1998) Short Form 36 (SF36) Health Survey: Normative Data from the General Norwegian Population. Scandinavian Journal of Social Medicine, 26, 250-259.
[10]
Lindvall, O., Bjorklund, A. and Skagerberg, G. (1983) Dopamine-Containing Neurons in the Spinal Cord: Anatomy and Some Functional Aspects. Annals of Neurology, 14, 255-260. http://dx.doi.org/10.1002/ana.410140302
[11]
Mylius, V., Engau, I., Teepker, M., Stiasny-Kolster, K., Schepelmann, K., Oertel, W.H., Lautenbacher, S. and Moller, J.C. (2009) Pain Sensitivity and Descending Inhibition of Pain in Parkinson’s Disease. Journal of Neurology, Neurosurgery & Psychiatry, 80, 24-28. http://dx.doi.org/10.1136/jnnp.2008.145995
[12]
Brefel-Courbon, C., Payoux, P., Tahlmas, C., Ory, F., Quelven, I., Chollet, F., Montastruc, J.L. and Rascol, O. (2005) Effect of Levodopa on Pain Threshold in Parkinson’s Disease: A Clinical and Positron Emission Tomography Study. Movement Disorders, 20, 1557-1563. http://dx.doi.org/10.1002/mds.20629
[13]
Sato, Y., Iwamoto, J. and Honda, Y. (2011) Amelioration of Osteoporosis and Hypovitamininosis D by Sunlight Exposure in Parkinson’s Disease. Parkinsonism & Related Disorders, 17, 22-26.
http://dx.doi.org/10.1016/j.parkreldis.2010.10.008
[14]
Holick, M.F. (2007) Vitamin D Deficiency. The New England Journal of Medicine, 357, 266-281.
http://dx.doi.org/10.1056/NEJMra070553
[15]
Kamanli, A., Ardicoglu, O., Ozgocmen, S. and Yoldas, T.K. (2008) Bone Mineral Density in Patients with Parkinson’s Disease. Aging Clinical and Experimental Research, 20, 277-279. http://dx.doi.org/10.1007/BF03324774
[16]
Lam, K., Li, M., Mok, V., Hui, A. and Woo, J. (2010) A Case Control Study on Bone Mineral Density in Chinese Patients with Parkinson’s Disease. Parkinsonism & Related Disorders, 16, 471-474.
http://dx.doi.org/10.1016/j.parkreldis.2010.05.002
[17]
Taggart, H. and Crawford, V. (1995) Reduced Bone Density of the Hip in Elderly Patients with Parkinson’s Disease. Age and Ageing, 24, 326-328. http://dx.doi.org/10.1093/ageing/24.4.326
[18]
Lorefalt, B., Toss, G. and Granérus, A.K. (2007) Bone Mass in Elderly Patients with Parkinson’s Disease. Acta Neurologica Scandinavica, 116, 248-254. http://dx.doi.org/10.1111/j.1600-0404.2007.00875.x
[19]
Abou-Raya, S., Helmii, M. and Abou-Raya, A. (2009) Bone and Mineral Metabolism in Older Adults with Parkinson’s Disease. Age and Ageing, 38, 675-680. http://dx.doi.org/10.1093/ageing/afp137
[20]
Bezza, A., Ouzzif, Z., Naji, H., Achemlal, L., Mounach, A., Nouijai, M., Bourazza, R., Mossadeq, A. and Maghraoui, E.I. (2008) Prevalence and Risk Factors of Osteoporosis in Patients with Parkinson’s Disease. Rheumatology International, 28, 1205-1209. http://dx.doi.org/10.1007/s00296-008-0632-6
[21]
Sato, Y., Kaji, M., Tsuru, T., Satoh, K. and Kondo, I. (2002) Vitamin K Deficiency and Osteopenia in Vitamin D-De- ficient Elderly Women with Parkinson’s Disease. Archives of Physical Medicine and Rehabilitation, 83, 86-91.
http://dx.doi.org/10.1053/apmr.2002.27376
